| Association of race with cumulative exposure to statins in dialysis. | |
| | |
MedLine Citation:
|
PMID: 22739257 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients on dialysis have high rates of cardiovascular disease and are frequently treated with HMG-CoA reductase inhibitors. Given that these patients have insurance coverage for medications as well as regular contact with health care providers, differences by race in exposure to statins over time should be minimal among patients who are candidates for the drug. METHODS: We created a cohort of incident dialysis patients who were dually eligible for Medicare and Medicaid services. We determined the proportion of days covered (or PDC, a marker of cumulative medication exposure) by a statin prescription over a mean of 2.0 ± 1.4 years. Ordinary least squares regression was used to determine the factors associated with cumulative drug exposure. RESULTS: Of the 18,727 patients who filled at least one prescription for a statin, mean PDC was 0.57 ± 0.32. The unadjusted PDC was higher for Caucasians (0.63 ± 0.31) than for African-Americans (0.51 ± 0.32), Hispanics (0.54 ± 0.31), and individuals of other race/ethnicity (0.58 ± 0.32). In multivariable modeling, Caucasian race was independently associated with greater exposure to statins. Relative to Caucasians, the adjusted odds ratios for the PDC for African-Americans was 0.47 (95% confidence interval, CI, 0.43-0.50), for Hispanics 0.52 (0.48-0.56) and for others, 0.72 (0.64-0.81). CONCLUSIONS: Despite insurance coverage, regular contact with health care providers, and at least one prescription for a statin, there are large differences by race in statin exposure over time. The provider- and patient-associated factors related to this phenomenon should be further examined. |
| | |
Authors:
|
James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman |
Related Documents
:
|
11980977 - Microsatellite characterization of plasmodium falciparum from cerebral and uncomplicate... 22669407 - Drip-and-ship thrombolytic treatment paradigm among acute ischemic stroke patients in t... 15757017 - Severe falciparum malaria simulating fulminant hepatic failure. 21502957 - Characterization of spinal cord lesion in patients attending a specialized rehabilitati... 16462757 - Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (risct)... 2298377 - Candida-associated diarrhea in hospitalized patients. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-06-27 |
Journal Detail:
|
Title: American journal of nephrology Volume: 36 ISSN: 1421-9670 ISO Abbreviation: Am. J. Nephrol. Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-07-20 Completed Date: 2012-11-29 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 8109361 Medline TA: Am J Nephrol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 90-6 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 S. Karger AG, Basel. |
Affiliation:
|
Division of Nephrology and Hypertension, Department of Medicine, University of Kansas School of Medicine, Kansas City, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Cardiovascular Diseases / therapy Cohort Studies Ethnic Groups Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Least-Squares Analysis Male Medicaid Medicare Middle Aged Odds Ratio Regression Analysis Renal Dialysis / methods* Social Class United States |
| Grant Support | |
ID/Acronym/Agency:
|
K23 DK085378-01/DK/NIDDK NIH HHS; R01 DK080111/DK/NIDDK NIH HHS; R01 DK080111-02/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of Intensity-modulated Radiotherapy in Oropharyngeal Cancer.
Next Document: Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development.